RU2643809C2 - Модуляторы киназ aurora и flt3 - Google Patents

Модуляторы киназ aurora и flt3 Download PDF

Info

Publication number
RU2643809C2
RU2643809C2 RU2014131784A RU2014131784A RU2643809C2 RU 2643809 C2 RU2643809 C2 RU 2643809C2 RU 2014131784 A RU2014131784 A RU 2014131784A RU 2014131784 A RU2014131784 A RU 2014131784A RU 2643809 C2 RU2643809 C2 RU 2643809C2
Authority
RU
Russia
Prior art keywords
compound
aurora
kinase
hydrogen
compounds
Prior art date
Application number
RU2014131784A
Other languages
English (en)
Russian (ru)
Other versions
RU2014131784A (ru
Inventor
Джон Чарльз РИДЕР
Original Assignee
Сареум Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сареум Лимитед filed Critical Сареум Лимитед
Publication of RU2014131784A publication Critical patent/RU2014131784A/ru
Application granted granted Critical
Publication of RU2643809C2 publication Critical patent/RU2643809C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2014131784A 2012-02-06 2013-02-04 Модуляторы киназ aurora и flt3 RU2643809C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1202027.7 2012-02-06
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (2)

Publication Number Publication Date
RU2014131784A RU2014131784A (ru) 2016-03-27
RU2643809C2 true RU2643809C2 (ru) 2018-02-06

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014131784A RU2643809C2 (ru) 2012-02-06 2013-02-04 Модуляторы киназ aurora и flt3

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2805932C2 (ru) * 2018-10-08 2023-10-24 Сареум Лимитед Фармацевтические соединения

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024980A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors
EA200970612A1 (ru) * 2006-12-21 2009-10-30 Глэксо Груп Лимитед Производные индола в качестве агонистов рецептора s1p1
WO2010055304A2 (en) * 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024980A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
EA200970612A1 (ru) * 2006-12-21 2009-10-30 Глэксо Груп Лимитед Производные индола в качестве агонистов рецептора s1p1
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors
WO2010055304A2 (en) * 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2805932C2 (ru) * 2018-10-08 2023-10-24 Сареум Лимитед Фармацевтические соединения

Also Published As

Publication number Publication date
CN104169277B (zh) 2016-10-12
MX338481B (es) 2016-04-19
SG11201404277WA (en) 2014-08-28
DK2812328T3 (en) 2016-01-11
BR112014019254A8 (pt) 2017-07-11
IL233988A (en) 2017-06-29
RU2014131784A (ru) 2016-03-27
CN104169277A (zh) 2014-11-26
GB201202027D0 (en) 2012-03-21
PL2812328T3 (pl) 2016-04-29
JP2015511228A (ja) 2015-04-16
AU2013218167B2 (en) 2017-04-06
BR112014019254B1 (pt) 2020-03-10
US20150018367A1 (en) 2015-01-15
US9133180B2 (en) 2015-09-15
CA2863759C (en) 2020-04-14
WO2013117522A1 (en) 2013-08-15
CA2863759A1 (en) 2013-08-15
EP2812328A1 (en) 2014-12-17
JP6034880B2 (ja) 2016-11-30
PT2812328E (pt) 2016-03-01
HK1204327A1 (en) 2015-11-13
BR112014019254A2 (enExample) 2017-06-20
KR20140128373A (ko) 2014-11-05
AU2013218167A1 (en) 2014-08-14
MX2014009323A (es) 2015-04-08
ES2560260T3 (es) 2016-02-18
EP2812328B1 (en) 2015-11-18
KR102052780B1 (ko) 2019-12-05

Similar Documents

Publication Publication Date Title
JP2022508055A (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CA2901022A1 (en) Substituted pyridine compounds as inhibitors of histone demethylases
KR20190086442A (ko) 피리딘 화합물
CN109776445A (zh) 苯并噁二唑类化合物及其制备方法和医药用途
CN102725283A (zh) 作为蛋白激酶抑制剂的化合物和组合物
WO2021260111A1 (en) Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
JP2023520330A (ja) 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤
WO2010007374A1 (en) Pharmaceutical compounds
KR20210110664A (ko) Tam 및 met 키나제의 억제제로서의 퀴놀린 화합물
Fukuda et al. Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant
JP6034880B2 (ja) オーロラおよびｆｌｔ３キナーゼモジュレーター
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
KR20240099239A (ko) 결장직장암에 대한 전임상 활성을 갖는 종양원성 chd1l의 소분자
TW202412809A (zh) 包含標靶療法的抗癌組合
CA3195794A1 (en) Dosing regimens for cyclin?dependent kinase 7 (cdk7) inhibitors
HK1204327B (en) Aurora and flt3 kinases modulators
RU2720180C2 (ru) Соединения, применяемые в лечении неопластических заболеваний
CN116589464A (zh) 嘧啶并环类化合物、其制备方法和应用